Evgen Pharma(GB:TCF)
GBXÂ 0.170.00 (0.00%)
GB:TCF
Evgen Pharma financials statements
GBXÂ 0.17
At close:0.00 (0.00%)
Want to see GB:TCF full AI Analyst Report?
Evgen Pharma (TCF) Ratios
4 Followers
Evgen Pharma Ratios
GB:TCF's free cash flow for Q4 2025 was £-1.86M. For the 2025 fiscal year, GB:TCF's free cash flow was decreased by £-17.00K and operating cash flow was £-1.85M. See a summary of the company’s cash flow.
| Ratios | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.36 | 3.11 | 4.20 | 7.36 | 23.31 |
| Quick Ratio | 1.36 | 3.11 | 4.20 | 7.36 | 23.31 |
| Cash Ratio | 0.28 | 1.27 | 2.78 | 6.00 | 10.97 |
| Solvency Ratio | -1.68 | -1.13 | -4.34 | -4.84 | -6.60 |
| Operating Cash Flow Ratio | -1.51 | -1.42 | -4.16 | -4.84 | -6.23 |
| Short-Term Operating Cash Flow Coverage | -231.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | £ 193.00K | £ 3.51M | £ 2.31M | £ 5.29M | £ 9.17M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.77 | 1.28 | 1.31 | 1.16 | 1.04 |
| Debt Service Coverage Ratio | -330.18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Debt to EBITDA | 0.13 | 1.03 | 0.56 | 1.00 | 1.43 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 97.22% | 97.06% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | -898.99% | -1132.58% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | -896.21% | -1129.64% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | -898.99% | -1147.06% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | -900.51% | -1132.58% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | -792.17% | -914.71% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | -792.17% | -914.71% | 0.00% |
| Net Income Per EBT | 98.96% | 93.09% | 87.97% | 80.76% | 86.15% |
| EBT Per EBIT | 96.82% | 98.16% | 100.17% | 98.74% | 99.31% |
| Return on Assets (ROA) | -73.35% | -25.44% | -102.45% | -65.48% | -28.33% |
| Return on Equity (ROE) | -129.96% | -32.52% | -134.00% | -75.70% | -29.59% |
| Return on Capital Employed (ROCE) | -117.81% | -35.59% | -152.07% | -94.93% | -34.58% |
| Return on Invested Capital (ROIC) | -116.18% | -35.59% | -133.78% | -76.67% | -29.79% |
| Return on Tangible Assets | -153.52% | -37.54% | -103.60% | -65.94% | -28.48% |
| Earnings Yield | -84.33% | -160.25% | -134.26% | -39.75% | -28.38% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.80 | 0.44 | 0.00 |
| Payables Turnover | 0.01 | 19.92 | 0.03 | 0.03 | 0.24 |
| Inventory Turnover | 0.00 | 0.00 | -11.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 396.00 | 147.33 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.13 | 0.07 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.10 | 0.06 | 0.00 |
| Cash Conversion Cycle | -38210.94 | -18.32 | -10525.09 | -10447.92 | -1505.63 |
| Days of Sales Outstanding | 0.00 | 0.00 | 458.09 | 839.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | -33.18 | 0.00 | 0.00 |
| Days of Payables Outstanding | 38210.94 | 18.32 | 10950.00 | 11286.92 | 1505.63 |
| Operating Cycle | 0.00 | 0.00 | 424.91 | 839.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
| Dividend Paid and CapEx Coverage Ratio | -149.82 | 0.00 | 0.00 | -4029.00 | -853.33 |
| Capital Expenditure Coverage Ratio | -149.82 | 0.00 | 0.00 | -4029.00 | -853.33 |
| Operating Cash Flow Coverage Ratio | -231.55 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | -7.57 | -9.12 | 0.00 |
| Free Cash Flow Yield | -61.23% | -195.43% | -128.22% | -39.62% | -26.64% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.22 | -0.63 | -0.74 | -2.52 | -3.52 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 5.90 | 23.01 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.54 | 0.20 | 1.00 | 1.90 | 1.04 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.63 | -0.51 | -0.78 | -2.52 | -3.75 |
| Price-to-Operating Cash Flow Ratio | -1.64 | -0.51 | -0.78 | -2.52 | -3.76 |
| Price-to-Earnings Growth (PEG) Ratio | 0.02 | 0.01 | 0.03 | -0.05 | 0.08 |
| Enterprise Value Multiple | -1.02 | 0.44 | -0.09 | -1.04 | -1.62 |
| Enterprise Value | 3.73M | -897.80K | 332.55K | 5.17M | 5.11M |
| EV to EBITDA | -1.02 | 0.44 | -0.09 | -1.04 | -1.62 |
| EV to Sales | 0.00 | 0.00 | 0.84 | 11.70 | 0.00 |
| EV to Free Cash Flow | -1.45 | 0.38 | -0.11 | -1.28 | -1.99 |
| EV to Operating Cash Flow | -1.46 | 0.38 | -0.11 | -1.28 | -2.00 |
| Tangible Book Value Per Share | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 |
| Shareholders’ Equity Per Share | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | -0.07 | 0.12 | 0.19 | 0.14 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.01 |
| Tax Burden | 0.99 | 0.93 | 0.88 | 0.81 | 0.86 |
| Interest Burden | 0.97 | 0.98 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 6.99 | 10.68 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 2.93 | 1.73 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.35 | 0.36 | 0.00 |
| Income Quality | 0.72 | 1.14 | 0.84 | 1.00 | 0.94 |
Currency in GBP

